Cargando…
Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
Definitive chemoradiotherapy (dCRT) for the esophageal squamous cell carcinoma (ESCC) is performed for patients with cT4 disease without distant metastasis and also for those with cStage I‐III who are unable to tolerate or who refuse surgery. The rates of clinical complete response (cCR) after dCRT...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316734/ https://www.ncbi.nlm.nih.gov/pubmed/34337292 http://dx.doi.org/10.1002/ags3.12448 |
_version_ | 1783729924281991168 |
---|---|
author | Yagi, Koichi Toriumi, Tetsuro Aikou, Susumu Yamashita, Hiroharu Seto, Yasuyuki |
author_facet | Yagi, Koichi Toriumi, Tetsuro Aikou, Susumu Yamashita, Hiroharu Seto, Yasuyuki |
author_sort | Yagi, Koichi |
collection | PubMed |
description | Definitive chemoradiotherapy (dCRT) for the esophageal squamous cell carcinoma (ESCC) is performed for patients with cT4 disease without distant metastasis and also for those with cStage I‐III who are unable to tolerate or who refuse surgery. The rates of clinical complete response (cCR) after dCRT differ depending on the cStage, and patients who once achieved cCR frequently experience tumor recurrence. For those with residual tumor or with recurrence, salvage treatment is performed to achieve a cure. Several procedures have been reported as salvage treatments. Salvage esophagectomy is associated with high rates of morbidity and mortality, but can offer long‐term survival. With R0 resection, with cCR to dCRT, pulmonary complications appear to be important prognostic factors affecting overall survival (OS). Lymphadenectomy is performed for the patients with lymph node metastasis without recurrence of primary lesions or distant metastasis, but the contribution to long‐term OS is unclear. Metastasectomy is performed when distant metastasis is limited to the lung and there are few lesions, possibly contributing to long‐term OS. Endoscopic resection and photodynamic therapy are indicated for cT1a and cT1‐2 residual or recurrent tumors, respectively, and can yield favorable outcomes. Re‐CRT and re‐radiotherapy are performed for the patients with contraindications for surgery, but neither appears to contribute to long‐term OS despite high incidences of esophageal fistula and perforation. |
format | Online Article Text |
id | pubmed-8316734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83167342021-07-31 Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma Yagi, Koichi Toriumi, Tetsuro Aikou, Susumu Yamashita, Hiroharu Seto, Yasuyuki Ann Gastroenterol Surg Review Articles Definitive chemoradiotherapy (dCRT) for the esophageal squamous cell carcinoma (ESCC) is performed for patients with cT4 disease without distant metastasis and also for those with cStage I‐III who are unable to tolerate or who refuse surgery. The rates of clinical complete response (cCR) after dCRT differ depending on the cStage, and patients who once achieved cCR frequently experience tumor recurrence. For those with residual tumor or with recurrence, salvage treatment is performed to achieve a cure. Several procedures have been reported as salvage treatments. Salvage esophagectomy is associated with high rates of morbidity and mortality, but can offer long‐term survival. With R0 resection, with cCR to dCRT, pulmonary complications appear to be important prognostic factors affecting overall survival (OS). Lymphadenectomy is performed for the patients with lymph node metastasis without recurrence of primary lesions or distant metastasis, but the contribution to long‐term OS is unclear. Metastasectomy is performed when distant metastasis is limited to the lung and there are few lesions, possibly contributing to long‐term OS. Endoscopic resection and photodynamic therapy are indicated for cT1a and cT1‐2 residual or recurrent tumors, respectively, and can yield favorable outcomes. Re‐CRT and re‐radiotherapy are performed for the patients with contraindications for surgery, but neither appears to contribute to long‐term OS despite high incidences of esophageal fistula and perforation. John Wiley and Sons Inc. 2021-03-10 /pmc/articles/PMC8316734/ /pubmed/34337292 http://dx.doi.org/10.1002/ags3.12448 Text en © 2021 The Authors. Annals of Gastroenterological Surgery published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Yagi, Koichi Toriumi, Tetsuro Aikou, Susumu Yamashita, Hiroharu Seto, Yasuyuki Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
title | Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
title_full | Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
title_fullStr | Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
title_full_unstemmed | Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
title_short | Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
title_sort | salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316734/ https://www.ncbi.nlm.nih.gov/pubmed/34337292 http://dx.doi.org/10.1002/ags3.12448 |
work_keys_str_mv | AT yagikoichi salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma AT toriumitetsuro salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma AT aikoususumu salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma AT yamashitahiroharu salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma AT setoyasuyuki salvagetreatmentafterdefinitivechemoradiotherapyforesophagealsquamouscellcarcinoma |